Gal Wald
@WaldoGMed
Followers
153
Following
260
Media
2
Statuses
30
PGY-5 at @WCMUrology | @WeillCornell @Cornell Alum via @NIH
Joined April 2020
Pooling PREVENT 1 AND PREVENT 2 RCTs demonstrated no difference in cancer detection or prevalence of anterior tumor location using TP vs TR biopsy for Black men vs. others: Association Between Race and Detection of Clinically Significant PCa https://t.co/63qr6JdcT1
0
8
24
Alliance researcher @eugene_pietzak @MSKCancerCenter leads @ALLIANCE_org A032303/GAIN-BCG, a trial evaluating a two-step treatment approach for pts w/BCG-unresponsive non–muscle-invasive #bladdercancerome. Learn more: https://t.co/mjpt3I0t2n
#NCI #NCTN #CancerResearch #NMIBC
0
11
41
👀comprehensive review (and table) of RCTs for Transperineal vs transrectal prostate biopsy by super⭐️@EvanSuzman @UTSWMedCenter MS4 @nyphospital @WeillCornell @WCMUrology Review of Transperineal and Transrectal Prostate Biopsy Outcomes https://t.co/U0ib5Ix8Q9
3
10
37
👀 ⭐️@WaldoGMed @nyphospital @KeithKow @GUUrology 10th @EUplatinum journals Surgery in Motion. Largest comparison of Hood, Retzius vs Std Robotic RP: Retzius>Hood>Std continence recovery, but ⬆️ Retzius + SMs https://t.co/KsFVOmOgeO
1
13
64
Congratulations to our current chief residents, Drs. Lina Posada Calderon & Oakley Strasser on their urologic oncology fellowship matches! We are so proud of all you have accomplished throughout your residency, and we wish you luck as you both begin your fellowships next year!
1
10
94
Thank you for the wonderful year @jimhumd Incredible way to round it out and begin PGY5
High performer celebration of the end of: (1) R4 @nyphospital @WCMUrology research year for @WaldoGMed; (2) @UroOnc fellowship for @parwizabrahimi
1
1
21
Humbled and honored to be among this year’s @ConquerCancerFd YIA grant recipients. Indebted to my mentors — Dr. @eugene_pietzak , Dr. @IyerGopa , and the team at @UrologyMSK @MSKCancerCenter — for their unwavering guidance and support. Excited for the future #ASCO25
Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: https://t.co/aE89Mrvgeu
@ASCO
4
2
27
Jim C. Hu, MD, (@jimhumd) details findings from a study comparing urinary continence recovery across standard, Retzius-sparing, and Hood RARP techniques. #AUA25 @WCMUrology
https://t.co/596oEWBq6h
urologytimes.com
Jim C. Hu, MD, MPH, shares in-depth findings comparing urinary continence recovery across 3 RARP approaches.
1
9
29
Highlights from #SUO24! @AmyLuckenbaugh @VUMChealth & @UroCancerMD @VUMCurology dive into late-breaking #bladdercancer trials—combo intravesical gem/BCG for BCG-exposed & phase III cretostimogene in BCG-unresponsive CIS. Key takeaway? More options than ever for #NMIBC, with
0
3
8
Studies and clinical trials related to decision-making insights and market demand for early infant male circumcision with ShangRing in Kenya, Tanzania, and Uganda received great attention at the 2025 AUA. @LinaPosadaCald and @ @WaldoGMed did an excellent job showcasing our work
0
4
14
Recovery of urinary continence after robotic-assisted radical prostatectomy: A multicenter comparison of Retzius-sparing, hood, and standard techniques. Presented by @WaldoGMed @WCMUrology. #AUA25 written coverage by @zklaassen_md @GACancerCenter on UroToday >
4
10
25
Congratulations to Aaron Gurayah, MD (@AGurayah), PGY2 resident, for winning best poster for his research on barriers to prostate cancer screening under the mentorship of Dr. Meena Davuluri (@MeenaDavuluri) at #AUA25! We are so proud of you!
5
3
38
We are so excited for #AUA25 to begin in few weeks! Our faculty, fellows and residents are looking forward to participating in a variety of sessions as well as connecting with colleagues. Scroll⏬ to learn more about what our trainees will be presenting during the meeting.
1
2
15
Comparative outcomes of intralesional #collagenase injection for #PeyroniesDisease: acute vs. stable phase treatment👉 https://t.co/ScA4uAiwdE
@manishkuch @nyphospital @WeillCornell @HBhambhvani @WCMUrology @WaldoGMed
0
6
21
Phase II trial explores gemcitabine + BCG for BCG-exposed #BladderCancer. @eugene_pietzak @MSKCancerCenter & @WaldoGMed @WCMUrology join @UroCancerMD @VUMCurology to discuss this phase II trial that demonstrates promising results with a 94% complete response rate at six months
0
14
35
@ASCO #GU25 Poster Session #BladderCancer @UrologyMSK @UroMuneeb @eugene_pietzak E6- The impact of micropapillary histology and clinical staging on OS ✨130 pts ✨Presence of micropappillary predicts poor prognosis, regardless of its proportion ‼️ 👉The key predictor of
1
8
16
Video in @UroToday: @UroCancerMD chats with @waldogmed and @eugene_pietzak about intravesical gemcitabine and BCG combination therapy for BCG-exposed non-muscle-invasive bladder cancer. Click to watch the video:
0
3
1
Gal Wald, MD, shares the rationale for a trial of BCG plus gemcitabine in high-grade NMIBC. #SUO24 @WaldoGMed @WCMUrology
https://t.co/vLwYeooonS
urologytimes.com
"Combination therapies have now become the forefront of our field, and we are trying to do better to avoid BCG-unresponsive disease, as well as progression to either muscle-invasive or metastatic...
0
8
19